Stephens Inc. AR Purchases 35 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Stephens Inc. AR grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 752 shares of the company’s stock after buying an additional 35 shares during the period. Stephens Inc. AR’s holdings in Medpace were worth $250,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Centaurus Financial Inc. boosted its stake in shares of Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after buying an additional 29 shares during the period. Lindenwold Advisors INC raised its position in shares of Medpace by 1.6% in the 3rd quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock valued at $676,000 after buying an additional 32 shares in the last quarter. M&T Bank Corp lifted its holdings in shares of Medpace by 1.2% during the 3rd quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock worth $1,068,000 after acquiring an additional 37 shares during the period. Custom Index Systems LLC boosted its position in shares of Medpace by 3.0% during the 4th quarter. Custom Index Systems LLC now owns 1,290 shares of the company’s stock worth $429,000 after acquiring an additional 37 shares in the last quarter. Finally, Nations Financial Group Inc. IA ADV increased its stake in Medpace by 1.7% in the third quarter. Nations Financial Group Inc. IA ADV now owns 2,376 shares of the company’s stock valued at $793,000 after acquiring an additional 39 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on MEDP shares. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Robert W. Baird upped their price objective on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. William Blair reiterated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Finally, TD Cowen lowered their target price on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Trading Down 0.7 %

NASDAQ:MEDP opened at $340.17 on Monday. The stock’s 50-day moving average is $343.50 and its 200-day moving average is $348.07. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77. The stock has a market cap of $10.57 billion, a P/E ratio of 29.79, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 17.66% and a return on equity of 50.87%. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.